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Laser interstitial thermal therapy (LITT) is gaining popularity in the treatment of both primary 
and secondary intracranial tumors. The goal of LITT is to deliver thermal energy in a predictable, 
controlled, and minimally invasive fashion. It can be particularly valuable in patients with recurrent 
tumors who, due to previous radiation or surgery, may have a potentially higher risk of wound 
breakdown or infection with repeat craniotomy. Deep‑seated lesions that are often inaccessible 
through open approaches (thalamus, hypothalamus, mesial basal temporal lobe, brainstem) may 
also be suitable targets. The experience and data published thus far on this modality is limited but 
growing. This review highlights the use of LITT as a primary treatment method in a variety of 
intracranial tumors, as well as its application as an adjunct to established surgical techniques.
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Introduction
The concept of laser interstitial thermal 
therapy (LITT) for tumors has existed since 
the late 1970s. Technical limitations of 
appropriate laser systems, lack of accurate 
targeting of desired treatment areas, 
and the inability to monitor the thermal 
effects produced were some of the reasons 
limiting the widespread application of this 
technique. In 1983, Bown et al. reported 
the use of a neodymium‑doped yttrium 
aluminum garnet (Nd:YAG) laser in an 
experimental brain tumor model achieving 
focal tissue coagulation.[1] Several animal 
studies followed by clinical trials recognize 
the viability of LITT in treating intracranial 
tumors, and in 1990, Sugiyama et al. 
first reported the use of LITT in treating 
brain tumors.[2] Multiple subsequent 
studies explored its utility in brain tumor 
ablation.[3‑10] Despite the availability of 
magnetic resonance thermography (MRT), 
a lack of sophisticated laser probes with 
in‑built cooling systems and unavailability 
of intraoperative magnetic resonance 
imaging (MRI) prevented this modality 
from gaining widespread usage. With 
advances in technology, the last decade has 
seen a resurgence in interest in the use of 
the technique.
Two systems are currently approved by the 
US Food and Drug Administration (FDA) 
for intracranial application: Monteris 
NeuroBlate (Monteris, Plymouth, 
Minnesota‑First approved in 2009) and 
the Medtronic Visualase (Medtronic, 
Minneapolis, Minnesota). The NeuroBlate 
uses a CO2 cooled Nd: YAG laser with a 
1064‑nm wavelength while the Visualase 
uses a saline‑cooled diode laser with a 
980‑nm wavelength.[11,12] The two systems 
differ slightly in their degree of tissue 
penetration with the NeuroBlate system 
being able to achieve slightly larger 
ablation volumes. Both systems employ a 
fiberoptic catheter placed under stereotactic 
guidance through which light energy is 
delivered to the target tissue in the form of 
thermal energy. The thermal energy causes 
protein denaturation, melting of membrane 
lipids, vessel sclerosis, and coagulation 
necrosis, which occurs at 60C, while 
apoptosis is triggered between 43C and 
60C. Based on the optical characteristics 
of the normal brain parenchyma and 
pathological tissue, the lesion created can 
be conformed to the boundaries of the 
target lesion. Following LITT, three zones 
can be identified on MRI. The innermost 
zone is the zone of coagulation necrosis, the 
second (peripheral) zone also has nonviable 
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tissue with increased interstitial fluid, and the outermost 
zone is the marginal zone consisting of edematous but 
viable surrounding brain parenchyma.[13]
The goal of this modality is to deliver thermal energy in a 
predictable and controlled fashion. This has been possible 
with MRI thermography providing real‑time imaging cues, 
which allows optimal heating of the target tissue without 
significant char formation or unintended normal tissue 
destruction. A small scalp incision and burr hole provide 
access to deep‑seated lesions, which would otherwise be 
difficult to reach through a traditional open craniotomy.[14,15]
Role in Primary Brain Tumors [Table 1]
Newly diagnosed high‑grade gliomas (HGGs), specifically 
the World Health Organization (WHO) Grade IV 
gliomas, have a dismal prognosis. Depending on age, 
preoperative Karnofsky Performance Scale, and extent 
of resection on initial surgery, overall survival (OS) is 
best estimated at 12–16 months. Similarly, recurrent 
HGGs have a poor prognosis overall, an estimated 
39 weeks for anaplastic astrocytomas, and 30 weeks 
for grade IV gliomas.[16] Several therapies have been 
tested for recurrent HGGs, including repeat craniotomy 
for cytoreduction, chemotherapeutic trials of repeat 
temozolomide, bevacizumab, gliadel wafer implantation, 
and more recently the approval of tumor treating fields.[17] 
With open surgery for recurrent lesions, the risk of wound 
complications may be higher and access to deep‑seated 
lesions may present a challenge. This is where LITT 
may have a role in appropriately selected patients.[15] 
Han et al. showed that while laser ablation is minimally 
invasive (less blood loss, less pain, early resumption of 
adjuvant treatment) it is not particularly beneficial when 
it comes to larger or amorphous lesions.[18] When such 
lesions are present, there is a need for multiple probes 
and repositioning, which will add to the duration of the 
surgery and the invasiveness of the procedure.
Several of the early reports on the use of LITT were on 
patients with recurrent HGG. In 1998, Reimer et al. 
presented their experience of four patients with recurrent 
high‑grade gliomas who were palliatively treated with 
LITT.[10] After LITT, all patients were clinically stable 
at 6 months with good local tumor control. In 2002, 
Leonardi et al., presented their work on 24 patients (seven 
low‑grade gliomas, eleven anaplastic astrocytomas, six 
grade IV gliomas) with mean survival times of 34, 30, and 
9 months, respectively.[19] Meantime to progression after 
LITT for the three histological subgroups were 16 months, 
10 months, and 4 months, respectively. In 2005 and 2006, 
Schwarzmaier et al. published their initial experience 
with a total of eighteen patients with recurrent grade IV 
glioma.[11,20] In their initial report, survival times of 16 
and 20 months was noted in two patients. In a subsequent 
report of sixteen patients, the survival time of 11.2 months 
was seen, significantly longer compared with historical 
controls. Compared to other treatment combinations, these 
were rather promising results for recurrent HGG.
In 2012, Jethwa et al., from the United States (US) and 
Carpentier et al., from France reported their experiences 
with the Visualase system.[21,22] In the series from the US, 
twenty patients were included of which seven had recurrent 
or newly diagnosed HGG. One patient in this group had 
malignant cerebral edema following the procedure requiring 
a decompressive hemicraniectomy. In the series from 
France, four patients were included with recurrent grade IV 
gliomas, and all of them achieved complete lesional 
ablation. The median progression‑free survival (PFS) was 
1 month, and the median OS was 10 months.[21,22]
In 2013, Sloan et al. reported their outcomes of ten patients 
with recurrent grade IV glioma in a phase 1 safety analysis, 
and noted a median OS of 10.5 months.[23] Three patients 
had new or worsening neurological deficits after the 
procedure, of which two were transient. One of the patients 
had a vascular injury resulting in a pseudoaneurysm, which 
was subsequently treated by endovascular means.
Similarly, Hawasli et al. reported their initial experience in 
2013.[24] It included eleven patients with newly diagnosed or 
recurrent HGGs out of the total study population of seventeen 
patients. In this patient cohort, progression within the 
observation period (0.1–11.2 months) was seen in five of the 
eleven patients. Recurrence‑free survival for recurrent HGG 
was noted to be 8.4 months, slightly higher than recurrent 
tumors treated with bevacizumab. The small patient number, 
however, does not allow one to generate any meaningful 
conclusion. Two of the glioma patients had postoperative 
transient neurological deficit, while one died from meningitis.
Mohammadi et al., in their report from 2014, enrolled 
34 patients with HGG who underwent LITT with 
the Neuroblate system.[25] This was a retrospective, 
nonrandomized study with a heterogeneous patient 
population. Sixteen patients with a new diagnosis, and 
eighteen patients with recurrent HGG were included. 
A 68% 1‑year survival rate and 5.1‑month median PFS 
rate was noted. Significant morbidity was associated 
with the procedure, with 13 of 34 patients having a 
neurological complication. Twenty‑three patients had 
recurrences after a median of 7.2 months of follow‑up; 
five within the treatment field, twelve at the periphery, 
five were outside the enhancing volume but within 2 cm, 
and one was remote. Importantly, a higher percentage of 
contrast‑enhancing tumor ablation was associated with 
increased survival (9.7 vs. 4.6 months, <0.05 cm3 of tumor 
remaining). This study signifies that the cytoreductive 
effect of hyperthermia can be considered equivalent to 
surgical debulking.
In 2016, Leuthardt et al. treated twenty patients with 
recurrent HGGs.[26] An interesting aspect of this report was 
the testing of the level of brain‑specific enolase as a marker 
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of blood‑brain‑barrier disruption, postulated to enhance 
drug delivery. In this patient cohort, no peri‑procedural 
complications were noted. Late clinical and radiological 
follow‑up was not recorded, although two cases of 
radiological progression were seen within 10 weeks of 
LITT. Thomas et al. recently published their series that 
included eight patients with newly diagnosed grade IV 
glioma and thirteen patients with recurrent disease.[27] 
This study is unique as it assessed the molecular status of 
the newly diagnosed grade IV group (greater proportion 
had IDH wild‑type GBMs). In this group, the median 
PFS and median OS was 2 and 8 months, respectively. 
Radiographic involution of the tumor was not seen in any 
patient. In the thirteen patients with recurrent disease, five 
had a demonstrable response with concurrent radiographic 
shrinkage of the tumor following ablation. Median PFS 
was 5 months, and the median OS was >7 months.
In a recent systematic review, open craniotomy for new 
or recurrent HGG in eloquent or deep‑seated areas, and 
minimally invasive laser ablation technique were assessed 
head to head.[28] Eight LITT studies with seventy‑nine 
patients and twelve craniotomy studies, including 
1,036 patients, were identified by the authors. Meta‑analysis 
demonstrated the extent of an ablation of 85.4% ± 
10.6% with brain LITT versus extent of resection of 
77.0% ± 40% with craniotomy. Analysis of complications 
revealed 5.7% (95% confidence interval [CI]: 1.8–11.6) 
Table 1: Studies on role of laser interstitial thermal therapy in primary brain tumors
Study Number of 
patients
Reported outcomes/complications System used
Reimer et al., 
1998[9]






24 (7 LGGs, 11 
AAs 6 GBMs)





Survival time after the diagnosis of recurrence was 16 and 20 months 




16 Median survival increased to 11.2 months Nd‑YAG laser
Jethwa et al., 
2012[19]
20 Complications: One case each of insertion related hemorrhage, diabetes 
insipidus and metabolic derangement, significant cerebral edema requiring 





4 Median PFS=1 month. Median OS=10 months
Complications: One transient supplementary motor area syndrome, one epileptic 
seizure, and one CSF leak
Visualase 
system
Sloan et al., 
2013[21]
10 Ten patients with recurrent GBM. Median OS=10.5 months
Complications: Three patients with new or worsening neurological deficits. One 
patient with a vascular injury resulting in a pseudoaneurysm
Neuroblate 
system
Hawasli et al., 
2013[22]
11 (HGGs) Eleven patients with newly diagnosed or recurrent HGGs: Five of eleven 
patients had progression. PFS for recurrent HGG=8.4 months. Complications: 






34 (HGG) Thirty‑four patients with HGG, Median PFS=5.1 months. 68% 1‑year survival 
rate 
Complications: Seven cases of worsening preoperative neurological deficits, 
one case of new seizure, one case of postoperative hyponatremia, one case of 







Two cases of radiological progression seen within 10 weeks of LITT Neuroblate 
system
Thomas et al., 
2016[25]
8 Eight newly diagnosed GBMs: median PFS=2 months, median survival=8 
months 




Barnett et al., 
2016[26]
79 Comparison between LITT (79 patients) and Craniotomy (1036 patients). 




48 (24 LITT, 
24 biopsy only)
Comparison of LITT with biopsy only patients. Median PFS=4.3 months and 
5.9 months, respectively. Median OS: 14.4 months and 15.8 months respectively 
Complications: Six cases of worsening neurological deficits, one case of DVT, 
and twenty cases of moderate to severe intratumoral bleeding
Neuroblate 
system
GBMs – Glioblastoma Multiformes; HGGs – High‑grade gliomas; LITT – Laser interstitial thermal therapy; PFS – Progression‑free 
survival; OS – Overall survival; DVT: Deep vein thrombosis, LGGs: Low grade gliomas, AAs: Anaplastic astrocytomas
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chance of major complication in the LITT procedure versus 
13.8% (95% CI: 10.3–17.9) for traditional craniotomy. This 
study was obviously limited by the low number of reported 
patients in the LITT group, making a direct comparison 
rather difficult.
In 2018, Mohammadi et al. reported the efficacy of laser 
ablation followed by standard chemo/radiotherapy for 
newly diagnosed grade IV glioma.[29] They also compared 
the results of laser ablation therapy (n = 24) to a matched 
cohort of patients who underwent only biopsy (n = 24) 
followed by chemo/radiotherapy. Overall, the median 
estimate of OS and PFS in the laser ablation cohort was 
14.4 and 4.3 months compared to 15.8 and 5.9 months for 
biopsy only cohort. They concluded that maximum tumor 
coverage by laser ablation followed by chemo/radiotherapy 
is an effective treatment modality, particularly for patients 
with high‑grade gliomas who are either unsuitable for 
aggressive surgery or choose not to undergo standard 
resection.
Role in Metastatic Lesions [Table 2]
In the landmark study by Patchell et al., surgical 
resection of a single focal metastatic lesion with adjuvant 
whole‑brain radiotherapy (WBRT) was shown to reduce 
local recurrence rates to 10% after 1 year.[30] This study 
was a paradigm shift in the standard of care for brain 
metastases. Currently, surgical resection, focal radiosurgery 
and/or WBRT, and systemic chemotherapy specific to the 
tumor type is utilized.[31] However, for certain deep‑seated 
metastatic lesions or recurrent disease, surgery or repeat 
radiation may not be an option.
In 2008, Carpentier et al., published their pilot clinical 
trial of LITT with real‑time MRI in focal intracranial 
metastatic lesions, which were resistant to standard 
therapy.[32] As a follow‑up to this in 2011, the same 
group reported their outcomes in phase I trial of seven 
patients receiving 15 treatments for breast and lung 
adenocarcinoma metastases. Tumor size in these patients 
did not exceed 30 mm. No major complications were noted 
in this series. Mean PFS was noted to be 3.8 ± 1 month. 
There was a difference between the fully treated subset 
and the partial treatment group. Median OS was estimated 
to be 17 months.[33] Hawasli et al., in their 2013 report 
also included five metastatic lesions.[24] Two patients had 
transient postoperative deficits. Out of the five patients, 
three had good local disease control, whereas the other 
two had central and systemic disease progression. Most 
recently, Chaunzwa et al., presented the results of a 
multi‑center retrospective study in which thirty patients 
with metastatic lesions were included. Good local control 
was noted at 6 months, reaching 93%. Twenty‑four lesions 
were biopsied, however only five of these revealed tumor 
four of which required a salvage craniotomy. The rest were 
consistent with radiation necrosis (RN).[34]
Another recent multicenter study by Ali et al., in 2016 
showed the use of LITT in postradiosurgery recurrence of 
metastatic lesions.[35] Twenty‑six lesions in twenty‑three 
patients who recurred after stereotactic radiosurgery (SRS) 
were treated with ablation. Nine lesions progressed despite 
treatment (35%). All cases of progression occurred in 
lesions with <80% ablation, whereas stability was achieved 
in those with ≥80% ablation. Five lesions were treated with 
a combination of laser ablation followed 1 month later by 
adjuvant SRS (5 Gy daily × 5 days). No disease progression 
was observed in these patients despite an ablation efficiency 
of <80%. This may suggest an augmented effect of laser 
ablation with SRS, or simply efficacy of the SRS itself, 
which has been shown to be effective up to three or more 
times in the same lesion.[36]
Role in Posttreatment Radiation Necrosis
Most treatment regimens for intermediate and high‑grade 
brain tumors require some form of radiation therapy as part 
of the treatment armamentarium. RN can occur as a result, 
and in certain cases, it can be severe enough to cause 
local mass effect and significant edema. It can also mimic 
tumor progression that may require resection through 
craniotomy, or repeat radiation, which may exacerbate the 
issue. The incidence of posttreatment RN has been reported 
to be as high as 50% with 16–22 Gy treatment dose. 
Table 2: Studies on role of laser interstitial thermal therapy in metastatic tumors
Study Number of patients Reported outcomes/complications System used
Carpienter 
et al., 2008[32]
4 (6 lesions) Gradual and steady decrease in lesion volume with no tumor recurrence 









Hawasli et al., 
2013[24]
5 (Mets) Median OS: 5.8 months. Two patients had transient postoperative deficits Neuroblate 
system
Ali et al., 
2016[35]
23 Lesions in which <80% ablation was achieved, 35% of these progressed
Complications: Three patients had transient hemiparesis, one developed 






30 OS: 52.3% at 6 months, 26.1% at 12 months, 21.8% at 18 months, and 
16.3% at 30 months
Neuroblate 
system
PFS – Progression‑free survival; OS – Overall survival
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Few therapeutic options are available for the treatment of 
this problem. Steroids temporarily alleviate the situation 
but are not a viable long‑term solution. Vitamin E and 
pentoxifylline have been tested, and recently a trial of 
intra‑arterial bevacizumab has been initiated (LIBERTI, 
Dashti et al.).[37,38] LITT has shown to have some promising 
effects as well. Laser ablation for RN targets not only 
the necrotic mass but also the peri‑necrotic region, which 
is the bed of vascular endothelial growth factor (VEGF) 
production. RN becomes symptomatic largely due to 
perilesional edema. This is driven by VEGF production, 
leading to disorganized angiogenesis. The obliteration of 
this peri‑necrotic region leads to an effective ablation. In 
the first description of this application, Rahmathulla et al. 
included a margin of 0.5 cm around the lesion and achieved 
good control.[39] Rao et al. in 2014 published their report of 
fifteen treatments in fourteen patients for previously treated 
metastatic disease, with either symptomatic recurrence or 
radiographic recurrence.[40] The lesions were considered to 
be either RN or metastatic disease, as no tissue diagnosis 
differentiating between the two was obtained before laser 
ablation. Good local control was achieved in twelve 
patients, with two requiring surgical resection after the 
failure of LITT. The median PFS was 37 weeks, and OS 
was 57%. The tissue pathology did not reveal any tumor 
cells in these two patients, indicating RN. In 2016, Smith 
et al., in their series of 25 patients with biopsy‑confirmed 
RN (four of whom were later found to have high‑grade 
glioma on craniotomy) showed the safety of LITT and 
possibly achieving local control of the RN.[41]
In 2018, Ahluwalia et al., published a multicenter 
prospective study of LITT ablation in patients with 
radiographic progression after stereotactic radiosurgery for 
brain metastases.[42] Forty‑two patients were included: 19 
with biopsy‑proven RN, twenty with the recurrent tumor, 
and three with no diagnosis. Twenty‑seven patients (64%) 
had complete data for the 12 weeks follow‑up, while 
sixteen patients (38%) had complete data for the full 
26 week follow‑up. Of the data available the local PFS 
for the group was 74% at 12 weeks and through the last 
follow‑up. When comparing the two groups based on 
pathology, they found local PFS was statistically different 
at 12 weeks (100% for RN vs 54% for tumor; P = 0.016) 
but not at the last follow‑up beyond 12 weeks (91% for RN 
vs. 62% for tumor; P = 0.166). OS for the whole group 
was 86.5% at 12 weeks and 72.2% at 26 weeks. For RN 
patients, OS survival was 100% at 12 weeks and 82.1% 
at 26 weeks. Despite positive results, the utility of this 
technique in improving OS quality of life remains to be 
determined definitively.
Role in Recurrent Dural Based Lesions
For recurrent meningiomas, standard therapy is re‑operation 
or conformal radiotherapy. Chemotherapeutic options have 
been tried with limited efficacy. With these recurrent 
lesions, laser ablation may hold some value. Ivan et al., in 
their series of five patients harboring previously resected 
and radiation, now recurrent convexity meningiomas and a 
solitary fibrous tumor, showed reasonable local control in 
three out of five cases with short term follow up.[43]
Role in Pediatric Brain Tumors
Laser ablation has not been used extensively in 
children harboring brain tumors. Tovar‑Spinoza, in 
their report from 2016, described their experience 
with eleven children harboring twelve lesions.[44,45] The 
pathologies included six pilocytic astrocytomas, one 
ependymoma, one medulloblastoma, two choroid plexus 
xanthogranulomas in one patient, one subependymal giant 
cell astrocytoma (SEGA), and one ganglioglioma. Six 
patients received LITT as first‑line therapy. Tumor volume 
decreased in the first 3 months after ablation and continued 
to decrease by the 4–6 month follow‑up. Two patients 
experienced postablation complications: transient right 
leg weakness in one patient, and transient hemiparesis, 
akinetic mutism, and eye movement disorder in the other. 
It is important to note that the intraventricular lesion was 
safely treated in this group of patients. Similarly, Dadey 
et al. also noted safe ablation of SEGAs in two patients in 
their report.[46] The first patient had recurrent disease, which 
was treated successfully with LITT. In the second patient, 
obstructive hydrocephalus was noted with tumor growth, 
prior to treatment with LITT. The patient was treated with 
robot‑guided LITT and a ventriculostomy for the resolution 
of hydrocephalus, resulting in good tumor control on 
subsequent imaging.
Other Neurosurgical Applications of Laser 
Interstitial Thermal Therapy
Chronic pain
Lesions in the cingulate gyrus have often been used for 
pain management in terminally ill cancer patients and in 
the management of psychiatric patients. In 2015, Patel 
et al. published their experience with MRI guided LITT 
in three patients with chronic refractory cancer‑related 
pain who underwent bilateral anterior cingulotomy.[47] 
These patients had failed multiple medication trials and 
interventions. The median preoperative pain severity (PSS) 
and pain interference score (PIS) were 7,7 (range: 7.5‑9.3) 
and 9.9 (range: 9.7–10.0), respectively. Postoperatively 
the median PSS and PIS were 1.6 (range 1.0 2.8) and 
2.0 (range 0.3–2.6), respectively. There was a significant 
reduction in pain medications requirement for all three 
patients in the follow‑up period, and no adverse effects 
were encountered in the procedure.
Spinal metastasis
Metastatic spinal disease is a source of significant morbidity 
in cancer patients.[48] An ideal minimally invasive surgical 
approach to spinal metastasis would achieve local tumor 
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control, allow for fast recovery, minimize postoperative 
pain and morbidity, and curtail delays in initiating or 
interrupting systemic therapies directed to the primary 
tumor. In 2015, Tatsui et al., retrospectively reviewed 
11 patients at their institute, all with spinal metastasis from 
histologies considered to have an unfavorable response to 
conventional external beam radiation therapy.[49] All patients 
underwent spinal laser interstitial thermal therapy (SLITT) 
with the Visualase laser system. The mean preoperative 
Visual Analog Scale (VAS) for pain was 6.8, while the 
VAS postoperatively at 30 and 60 days was 4.27 and 2.8, 
respectively. The mean preoperative VAS was significantly 
higher than the VAS 30 days postoperatively (P = 0.035) 
and 60 days postoperatively (P = 0.01). Furthermore, 
the mean thickness of the epidural tumor decreased 
significantly from 8.82 mm (95% CI 7.38–10.25) prior to 
treatment to 6.36 mm (95% CI 4.65–8.07) on the 2 months 
follow‑up images (P = 0.0001). They concluded that 
SLITT can be used as an alternative to separation surgery 
in patients without neurological deficits prior to spinal 
stereotactic radiosurgery.
Epilepsy surgery
Up to a third of epilepsy patients have seizures refractory 
to medical treatment. In patients with well‑localized 
drug‑resistant epilepsy (DRE), surgical resection of the 
epileptogenic zone (EZ) is highly effective with the overall 
quality of life benefits.[50] Magnetic resonance‑guided laser 
interstitial thermal therapy (MRgLITT) is an increasingly 
popular surgical option for DRE because it provides 
minimally invasive access anywhere in the brain with 
minimal disruption to overlying white matter and cortex. 
Curry et al., retrospectively reviewed the use of MRgLITT 
on five pediatric epilepsy patients whose seizures failed 
to improve from medical management with at least two 
anti‑epileptic drugs.[51] Postoperatively all patients remained 
without complications and were seizure‑free at follow‑up 
evaluations ranging 2–13 months. These results showed 
a significant potential for MRgLITT to offer a minimally 
invasive technique for ablation of epileptic foci.
Eloquent region pathologies
Intracranial lesions in functional areas of eloquence 
pose a challenge for surgical resection. In 2019, Kuo 
et al. presented their series of five pediatric patients 
with intracranial lesions in eloquent areas.[52] Clinical 
presentations included intractable epilepsy, hemiparesis, 
and aphasia by entities, including tumor, dysplasia, and 
RN. Postoperatively, all patients improved clinically and 
remained stable through follow‑up. Furthermore, in 2020 
Easawaran et al., presented the case of an 11‑year‑old boy 
with a growing left insular mass determined to be WHO 
grade II diffuse astrocytoma.[53] After the initial resection, 
the patient underwent laser ablation due to recurrence. At 
both 1‑ and 6‑month follow‑up the patient remained stable 
and seizure‑free. For intracranial lesions involving the 
eloquent cortex, open resection presents as a challenge and 
LITT can be used as a potentially effective option.
Discussion
LITT can be a valuable tool in patients harboring recurrent 
tumors who have a potentially higher risk of scalp 
breakdown or infection with repeat craniotomy due to 
previous radiation or surgery. Deep‑seated lesions which 
are inaccessible (thalamus, hypothalamus, mesial basal 
temporal lobe, brainstem, etc.) may also be suitable targets. 
LITT has shown some efficacy as an alternative to open 
craniotomy for deep‑seated metastatic lesions and recurrent 
gliomas, however, it is yet to be tested in a comparative 
large‑scale study. Similarly, for newly diagnosed HGG or 
easily accessible metastatic lesions, there is limited evidence 
to support its use as a first‑line treatment. Despite the 
minimally invasive approach (small skin incision and bone 
opening) the hyperthermia created can result in unwanted 
side effects, which be mitigated via open craniotomy 
approaches.[25] In addition to the above‑mentioned tumor 
types, other tumor types which are considered inoperable, 
such as bi‑hemispheric corpus callosum gliomas (butterfly 
lesions) may be an entity where combined with stereotactic 
biopsy for tissue diagnosis, LITT can play a role in 
achieving cytoreduction and thus improve the efficacy of 
adjuvant therapy. Use of fiber tractography and in certain 
cases angiography to better delineate the vascular anatomy 
can be helpful in planning targets and minimizing damage 
to adjacent white matter tracts and neurovascular structures.
Combination therapy with LITT, followed by craniotomy 
through minimally invasive trans tubular or trans‑sulcal 
approach, is an intriguing prospect. In the majority of 
reports, LITT has been used in isolation, and craniotomy 
for the lesion has been necessitated only if there has been 
malignant cerebral edema requiring decompression or if 
the tumor continues to show mass effect and associated 
symptoms requiring resection.[21,34,35] It is also important to 
understand that LITT has traditionally been used thus far for 
tumors <3 cm diameter and its use in larger tumors has been 
limited due to risk to adjacent vessels, white matter tracts, 
ventricular system and to prevent the induction of malignant 
edema. It does, however, raise the question that if these 
risks are all there and craniotomy will be attempted anyway, 
why perform laser ablation initially? Combining the two 
modalities appears to be similar to the treatment strategy 
for arteriovenous malformations and for certain skull base 
lesions, where preoperative embolization readily reduces the 
arterial inflow, thereby making the surgical resection less 
challenging. Laser ablation can be effective in coagulating 
the tumor and changing the consistency, which may allow 
a complete resection via a minimally invasive trans‑sulcal 
tubular approach rather than a larger craniotomy.[54,55] In this 
approach, the laser ablation acts as the actual cytoreduction 
therapy akin to maximal safe cytoreduction through open 
craniotomy, whereas the craniotomy is to reduce the mass 
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effect from the ablated tissue in large tumors. Wright et al. 
noted that in ten patients treated with LITT and subsequent 
craniotomy, the tumor was current jelly‑like and avascular 
when accessed using a trans tubular approach, making the 
operation much less involved.[55]
Some of the studies mentioned above have shown 
significant prolongation of OS and PFS for recurrent 
glioma patients, which may be tied in with the genetics 
and molecular markers of those tumors. It remains to be 
seen whether primary GBM compared to secondary GBM, 
with or without certain genetic mutations, would behave 
differently in comparison to each other.[56] Similarly, 
metastatic lesions of different origins may respond in a 
varied fashion to thermal ablation. LITT is a promising tool 
but will require extensive testing in a randomized control 
trial setting to understand the indications and effectiveness 
of this method before it is accepted as a standard of 
care. Currently, one trial is underway to assess LITT for 
pediatric central nervous system tumors.[57] Results are 
expected for another trial that finished recruiting in 2014 
for the treatment of metastatic brain tumors.[58]
Direct costs associated with laser ablation, including 
imaging and anesthesia, are estimated at about $56,127 
versus $50,447 for a craniotomy.[18] The time to perform 
either procedure is also comparable. However, variables 
such as team and surgeon experience, availability of relevant 
equipment, and ease of access to neuroimaging modalities 
can have a bearing. In 2016, Barnett et al. presented the 
value of using LITT in patients with high‑grade gliomas 
where maximal safe resection is not feasible.[59] They 
compared the overall costs in employing either LITT or 
standard of care treatments recommended by the National 
Comprehensive Cancer Network (NCCN) guidelines. At 
the time of the study, in the US cost‑effectiveness ratios 
of <$50,000/life year gained (LYG) was considered a 
good value, while internationally, it was considered to be 
at 30,000€ (or $32,575 in US dollars)/LYG (or at $2714/
month survival gained). They concluded that it would cost 
an additional $2445 for every month of survival gained 
in using LITT versus current treatment, but for HGGs 
residing in or near eloquent areas, which may require 
major open operations, LITT appeared to be cost‑effective. 
The LAANTERN study noted similar findings.[60] It also 
postulated that quality of life measures are likely improved 
in patients undergoing LITT compared to open craniotomy, 
due to the minimal invasiveness of the procedure. With low 
rates of complications and safety profile similar to a needle 
biopsy, it is possible that the volume of tissue ablation 
achieved would be similar to resection via craniotomy, 
therefore providing equivalent cytoreduction, similar 
survival outcomes, and improved quality of life.
Conclusion
LITT is gaining traction as one of the many tools 
currently available to neurosurgeons for the treatment of 
intracranial tumors. Despite accumulating evidence to 
suggest its efficacy and safety, particularly in the treatment 
of recurrent or deep‑seated gliomas and metastatic 
lesions, open craniotomy techniques remain standard of 
care. The prospect of combining LITT with minimally 
invasive craniotomy techniques is exciting. Cost may be a 
prohibitive factor, especially in developing countries.
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